Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance)

BACKGROUND: Anthracycline use in metastatic breast cancer (MBC) is hindered by cumulative exposure limits and risk of cardiotoxicity. Pixantrone, a novel aza-anthracenedione with structural similarities to mitoxantrone and anthracyclines, is theorized to exhibit less cardiotoxicity, mainly due to la...

Descripción completa

Detalles Bibliográficos
Autores principales: Sideras, Kostandinos, Hillman, David W, Giridhar, Karthik, Ginos, Brenda F, Tenglin, Richard C, Liu, Heshan, Chen, Beiyun, Tan, Winston, Gross, Gerald G, Mowat, Rex B, Dueck, Amylou C, Perez, Edith A, Moreno-Aspitia, Alvaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074972/
https://www.ncbi.nlm.nih.gov/pubmed/35445723
http://dx.doi.org/10.1093/oncolo/oyab065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074972/
https://www.ncbi.nlm.nih.gov/pubmed/35445723
http://dx.doi.org/10.1093/oncolo/oyab065

Ejemplares similares